Intermittent Claudication Clinical Trial
Official title:
Exercise Therapy in Patients With Peripheral Arterial Disease: the Costs and Effectiveness of Physiotherapeutic Supervision With or Without Therapy Feedback Versus a "go Home and Walk" Advice
The purpose of this study is to determine if supervised exercise therapy in a physiotherapeutic setting, with or without therapy feedback, is more (cost-)effective than exercise therapy based on a 'go home and walk' advice without supervision, for patients with PAD stage II (Fontaine).
Exercise therapy (ET) is considered to be the main conservative treatment for patients with intermittent claudication (IC) and is documented to be effective, especially when supervised. However, wide scale introduction of supervised ET in the Netherlands would lead to a substantial increase of health care costs compared to current practice, while the cost-effectiveness of supervised ET is uncertain. ET follows a pattern of short walking periods that induce discomfort of moderate intensity and short rest periods. The psychological, metabolic, and mechanical alterations that occur during exercise stimulate an adaptive response that ultimately reduces the symptoms. The optimal therapy regimen depends to a large extent on home-based exercises, which require discipline from the patient. Currently, the main prescription for ET for patients with IC in the Netherlands is a single 'go home and walk' advice, without supervision or follow-up. There is no evidence to support the effectiveness of this advice and compliance is low. In studies comparing the 'go home and walk' advice to supervised ET, a large advantage for supervised ET was present. The inadequate use of the main conservative treatment for peripheral arterial disease (PAD) contributes to a gradual progression of this condition, a decrease in quality of life, and an increasing number of vascular interventions. Furthermore, with adequate ET, hypertension, hypercholesterolemia, overweight, and diabetes, if present, is better regulated. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400395 -
Clinical Trial for GNX80 in Intermittent Claudication
|
Phase 4 | |
Active, not recruiting |
NCT02341716 -
Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication
|
N/A | |
Completed |
NCT02041169 -
Lower Extremity Peripheral Arterial Disease and Exercise Ischemia
|
N/A | |
Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
Recruiting |
NCT00538408 -
Whole Body Magnetic Resonance Angiography in Ischemic Patients
|
N/A | |
Completed |
NCT00618670 -
Home-based vs. Supervised Exercise for People With Claudication
|
N/A | |
Completed |
NCT00388128 -
Caffeine and Intermittent Claudication
|
Phase 3 | |
Recruiting |
NCT00146666 -
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
|
Phase 2 | |
Completed |
NCT00134277 -
Trial Comparing Different Medical Devices for Infragenual Dilatation
|
N/A | |
Completed |
NCT01256775 -
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
|
Phase 2 | |
Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06299956 -
Supervised Exercise-based Rehabilitation for People With Intermittent Claudication in Denmark
|
N/A | |
Not yet recruiting |
NCT05335161 -
A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
|
Phase 1 | |
Completed |
NCT04390282 -
Secondary Prevention and Application-based Lifestyle Support for Patients With Intermittent Claudication
|
N/A | |
Completed |
NCT03271710 -
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System
|
N/A | |
Completed |
NCT02380794 -
Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule
|
Phase 2 | |
Active, not recruiting |
NCT02276937 -
Randomized Phase IIb Trial of DVC1-0101
|
Phase 2 | |
Completed |
NCT02097082 -
Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System
|
N/A | |
Recruiting |
NCT00539266 -
Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia
|
Phase 2/Phase 3 | |
Completed |
NCT00071266 -
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
|
Phase 3 |